OSM560-April_DIGITAL_rev_Layout 1 4/8/13 11:09 AM Page 121
www.dantrium.com
*JHP's Dantrium® IV has a 36 month shelf life at manufacturing point. There is always some lag period between
manufacturing date and when the product ships to the end user, which varies based on when the order is placed.
Safety Information
Management of Malignant Hyperthermia (MH) crises requires various supportive measures individualized for the patient's condition. Administration of Dantrium® IV is
one component of therapy and should not be considered a substitute for these measures. Even when properly treated, an MH crisis can result in death. Adverse events
with Dantrium® IV include loss of grip strength, weakness in the legs, drowsiness, and dizziness, thrombophlebitis, and tissue necrosis/injection site reactions secondary
to extravasation. There have been rare reports of pulmonary edema, urticaria and erythema. Symptomatic hepatitis (fatal and non-fatal) has been reported at various
dose levels of the drug. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with Dantrium® therapy. In case of
overdose, symptoms include, but are not limited to, muscular weakness, lethargy, coma, vomiting, diarrhea, and crystalluria. For acute overdosage, general
supportive measures should be employed. Please visit www.dantrium.com for additional product information. For full prescribing information, please see reverse.
DAN3000-313
A P R I L 2 013 | O U T PAT I E N T S U R G E R Y M A G A Z I N E | 1 2 1
